Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Sexually Transmitted Diseases

Free Subscription Articles published in Gynecol Oncol Retrieve available abstracts of 13 articles: HTML format

Single Articles

September 2025
1. VAN DEN BORST E, Vanden Broeck D, De Sutter P, Donders G, et al
   EUROArray HPV test accuracy for cervical precancer in self- vs. clinician-collected samples using the VALHUDES protocol.
   Gynecol Oncol. 2025;202:14-23.
   PubMed     Abstract available
   
   
   
2. FULGIONE C, Inzani F, Raffone A, Raimondo D, et al
   Prognosis of HPV-independent, p53-wild-type vulvar squamous cell carcinoma: A systematic review and meta-analysis.
   Gynecol Oncol. 2025;201:210-215.
   PubMed     Abstract available
   
   
   March 2025
3. DE BONDT D, Naslazi E, Jansen E, Kupets R, et al
   Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies.
   Gynecol Oncol. 2025;195:134-143.
   PubMed     Abstract available
   
   
   January 2025
4. MIRZA HB, Hunt A, Ennis DP, McDermott J, et al
   Spatial transcriptomic analysis reveals significant differences in tumor microenvironment in HPV-dependent and HPV-independent vulvar squamous cell carcinoma.
   Gynecol Oncol. 2025;193:65-72.
   PubMed     Abstract available
   
   
   December 2024
5. WONG TY, Adzibolosu NK, Mattei LH, Speak AC, et al
   Disparities in contemporary human papilloma virus vaccination uptake among adult women living in the United States: An All of Us Research Program study.
   Gynecol Oncol. 2024;191:100-105.
   PubMed     Abstract available
   
   
   September 2024
6. LINDQUIST S, Kjaer SK, Frederiksen K, Ornskov D, et al
   Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study.
   Gynecol Oncol. 2024;191:45-55.
   PubMed     Abstract available
   
   
   January 2024
7. BEFANO B, Wentzensen N, Lorey T, Poitras N, et al
   Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.
   Gynecol Oncol. 2024;184:89-95.
   PubMed     Abstract available
   
   
   December 2023
8. WEBSTER EM, Ahsan MD, Kulkarni A, Penate E, et al
   Building knowledge using a novel web-based intervention to promote HPV vaccination in a diverse, low-income population.
   Gynecol Oncol. 2023;181:102-109.
   PubMed     Abstract available
   
   
   
9. VAHTERISTO M, Leinonen MK, Sarkeala T, Anttila A, et al
   Similar effectiveness with primary HPV and cytology screening - Long-term follow-up of randomized cervical cancer screening trial.
   Gynecol Oncol. 2023;180:146-151.
   PubMed     Abstract available
   
   
   November 2023
10. CHEN F, Zhang GN, Lei W, Zhou SG, et al
    Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study.
    Gynecol Oncol. 2023;178:8-13.
    PubMed     Abstract available
    
    
    May 2023
11. SCHIFFMAN M, Mirabello L, Egemen D, Befano B, et al
    The combined finding of HPV 16, 18, or 45 and cytologic Atypical Glandular Cells (AGC) indicates a greatly elevated risk of in situ and invasive cervical adenocarcinoma.
    Gynecol Oncol. 2023;174:253-261.
    PubMed     Abstract available
    
    
    
12. STOLER MH, Parvu V, Yanson K, Andrews J, et al
    Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
    Gynecol Oncol. 2023;174:68-75.
    PubMed     Abstract available
    
    
    March 2023
13. STOLER MH, Wright TC Jr, Parvu V, Yanson K, et al
    Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial.
    Gynecol Oncol. 2023;170:143-152.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Sexually Transmitted Diseases is free of charge.